Reverse Translational Medicine™ (RTM™)
Decoding the Secret of Life Through a Unique Research Approach
Reverse Translational Medicine™ (RTM™) - a Neurimmune core technology platform - leverages genetic blueprints derived from immune cells of elderly human subjects to generate fully human therapeutic antibodies. It is based on the scientific understanding and high-throughput analyses of human immune responses to disease-related proteins in selected populations including elderly with the capability to stay healthy during the aging process.
Leveraging the Genetic Blueprints of Life-Long Immune Memory
The RTM™ technology builds on the natural capabilities of the human immune system. Its fundamental mechanisms have been refined through millions of years of evolution, while adaptive immune responses generated throughout life are captured and preserved in long-lived immune memory cells - the ‘memory of life.’ By translating genetic information encoded in immune memory cells, this approach enables the discovery of highly selective, high-affinity antibody candidates. Guided by the natural processes of human affinity maturation and immune tolerance selection, the platform identifies antibodies that preferentially recognize pathological protein conformations while sparing their normal physiological counterparts. As a result, Neurimmune can develop antibody therapeutics that preserve essential biological functions while minimizing the risk of unwanted side effects.
At Neurimmune, we translate B-cell derived genetic information of human immune repertoires into transformative antibody therapeutics.
Jan Grimm, CSO